Company Profiles

driven by the PitchBook Platform

Oxagen

Description

Developer of small molecule drugs to treat inflammatory and respiratory diseases. The company's products comprise OC000459, an oral anti-inflammatory agent for the treatment of allergic disease, CRTH2 antagonist, an oral molecule for asthma, a pipeline of genetically validated GPCR targets for inflammatory and autoimmune diseases and CCRL2, an orphan C-C-chemokine receptor for the treatment of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis.

1996

Founded

PRIVATE

Status

51-200

Employees

Undetermined

Latest Deal Type

$169M

Total Amount Raised

13

Investors

Description

Developer of small molecule drugs to treat inflammatory and respiratory diseases. The company's products comprise OC000459, an oral anti-inflammatory agent for the treatment of allergic disease, CRTH2 antagonist, an oral molecule for asthma, a pipeline of genetically validated GPCR targets for inflammatory and autoimmune diseases and CCRL2, an orphan C-C-chemokine receptor for the treatment of rheumatoid arthritis, atherosclerosis, respiratory diseases, inflammatory bowel disease and allergic dermatitis.

Website:

www.oxagen.co.uk

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Pharmaceuticals

Primary Office

99 Park Drive Milton Park Abingdon OX14 4RYEngland +44 (0)12 3584 1561
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Oxagen's full profile, request a free trial.

Oxagen Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Oxagen Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Oxagen Investors (13)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
3i GroupPE/BuyoutMinority000 0000000 0000
Aberdeen SVG Private EquityPE/BuyoutMinority000 0000000 0000
Advent Venture PartnersVenture CapitalMinority000 0000000 0000
Bessemer Venture PartnersVenture CapitalMinority000 0000000 0000
International Biotechnology TrustOtherMinority000 0000000 0000
3i Group PE/Buyout
Aberdeen SVG Private Equity PE/Buyout
Advent Venture Partners Venture Capital
Bessemer Venture Partners Venture Capital
International Biotechnology Trust Other

Oxagen Executive Team (3)

NameTitleBoard
Seat
Contact
Info
Christine SodenChief Financial Officer
Mark EgertonExecutive
John Bell Ph.DCo-Founder & Board Member
Christine Soden Chief Financial Officer
Mark Egerton Executive
John Bell Ph.D Co-Founder & Board Member

Oxagen Board Members (8)

NameRepresentingRoleSinceContact
Info
Alan Ezekowitz Ph.DSelfBoard Member000 0000
Anja König Ph.DNovartis Venture FundsBoard Member000 0000
Erich SchlickWellington PartnersBoard Member000 0000
John Bell Ph.DOxagenCo-Founder & Board Member000 0000
Luke Evnin Ph.DMPM CapitalBoard Member000 0000
Alan Ezekowitz Ph.D Board Member Self
Anja König Ph.D Board Member Novartis Venture Funds
Erich Schlick Board Member Wellington Partners
John Bell Ph.D Co-Founder & Board Member Oxagen
Luke Evnin Ph.D Board Member MPM Capital
Request full access to PitchBook